The company’s lead in-house project is BT1718 – a bicycle toxin conjugate (BTC) drug that combines targeting of MT1-MMP on cancer cells with a cell-killing payload – which is being tested in ...

MMP-14 (also known as MT1-MMP) converts pro-MMP-2 into active MMP-2, and pro-MMP-9 can be activated by MMP-3 or oxidative modification. 11 Most studies have focused on gelatinases (MMP-2 and MMP-9) in ...

biconvex film coated tablets debossed with "M" on one side of break line on one side of the tablet and "MT1" on other side of the tablet. Available in blister packs 15 tablets. 47.5 mg ...